Magrolimab
Magrolimab Basic information
- Product Name:
- Magrolimab
- Synonyms:
-
- Magrolimab
- Research Grade Magrolimab(DHG17601)
- Magrolimab (anti-CD47)
- Hu5F9-G4|||Magrolimab (anti-CD47)
- Research Grade Magrolimab
- CAS:
- 2169232-81-7
- MW:
- 0
- Mol File:
- Mol File
Magrolimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Magrolimab Usage And Synthesis
Uses
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer[1][2][3].
in vivo
Magrolimab (12-100 μg; once daily; 10 days; i.p.) exhibits anti-tumor activity in mice with Ewing's sarcoma[1]. Magrolimab (250 μg; once every two days; 7 weeks; i.p.) combined with trastuzumab (HY-P9907) can eliminate HER2 positive breast cancer cells in breast cancer mice and overcome the tolerance of trastuzumab[2].
| Animal Model: | Humanized and non-humanized ES xenograft NSG-SGM3 mice[1]. |
| Dosage: | 12-100 μg |
| Administration: | Intraperitoneal injection (i.p.); once daily; 10 days |
| Result: | Inhibited tumor growth and lung metastasis, and prolonged animal survival time. |
| Animal Model: | 4-8 weeks old NSG female breast cancer mouse model[2]. |
| Dosage: | 250 μg |
| Administration: | Intraperitoneal injection (i.p.); once every two days; 7 weeks (implanted GFP/luciferase BT474 cells into the left mammary fat pad of female mice) |
| Result: | Restricted the Growth of HER2 ADCC-Tolerant Tumors. |
References
[1] Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. DOI:10.3389/fimmu.2023.1277987
[2] Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. DOI:10.1073/pnas.2026849118
[3] Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790. DOI:10.1016/j.lfs.2023.121790
MagrolimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com